NASH: A pandemic with an unmet need for pharmacotherapies

There is a significant medical need to find effective pharmacotherapies to manage NASH, the liver disease that is really a pandemic.The COVID pandemic firmly highlights the fact that liver disease is a big problem in our world, not just the U.S., as noted by the fact that patients with fatty liver disease do worse when infected with COVID-19. It’s interesting how that’s brought some light to fatty liver disease in the setting of this pandemic that we’re dealing with. But when we talk about treatments for NASH, there are three main target areas: the metabolic aspect, theRead More

Share on facebook
Share on twitter
Share on linkedin